Key Insights from the SELECT Trial

  • 30 MINUTES
  • NON-ACCREDITED
  • VIDEO
CVOTs have shown that GLP-1 receptor agonists reduce MACE in patients with T2D compared to placebo. In addition, they have a positive impact on several cardiovascular risk factors such as obesity by promoting weight loss, blood pressure and blood lipid levels. In this learning program Dr. Megha Poddar reviews key insights from the SELECT trial.

Presented by Megha Poddar, MD

View Faculty Details
View Learning Objectives

100% of the HCPs that took this program would recommend it to a colleague.

View Learner Feedback

Start Learning

Share this program with your peers